How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Progresses: The Natural History of ME/CFS.
Nacul, Luis, O'Boyle, Shennae, Palla, Luigi et al. · Frontiers in neurology · 2020 · DOI
Quick Summary
This study proposes a framework for understanding how ME/CFS develops and changes over time, similar to other long-term illnesses. The authors suggest that ME/CFS progresses through stages—starting with genetic and environmental risk factors, moving through an early phase with high energy use and immune system problems, and potentially progressing to a later phase with low energy production and multiple system involvement. They emphasize that ME/CFS is not the same in every person or at every stage of illness, and that some people may improve if their body can restore better balance.
Why It Matters
This framework helps explain why ME/CFS presents so differently between patients and why a single set of diagnostic criteria or biomarkers cannot capture everyone's experience. Understanding ME/CFS as a progressive condition with distinct stages may improve diagnosis, guide personalized treatment approaches, and help researchers design better studies that account for where patients are in their disease course.
Observed Findings
ME/CFS appears to involve distinct disease stages rather than a uniform presentation
Early disease is characterized by neuro-immune activation and high metabolic demand
Later disease may involve multiple system dysfunction and reduced energy production
Oxidative and nitrosative stress products may contribute to progressive cellular dysfunction
Some patients may experience improvement if homeostatic balance is restored
Inferred Conclusions
ME/CFS should be understood as a progressive condition evolving through multiple stages with varying pathophysiological features
Genetic factors, environmental exposures, and host immune responses interact to determine disease development and progression
The heterogeneity in ME/CFS presentation at different disease stages explains why single diagnostic criteria or biomarkers cannot represent all patients
Disease progression may not be uniformly linear; improvement is theoretically possible with adequate restoration of physiological homeostasis
Remaining Questions
What specific biomarkers or clinical features distinguish patients at each proposed disease stage?
What This Study Does Not Prove
This is a theoretical model, not a study of actual patient data, so it does not prove that all ME/CFS cases follow this progression pattern or timeline. The framework cannot establish causation for any specific pathophysiological mechanism, nor does it validate the proposed stages in clinical practice. The authors explicitly acknowledge gaps in research evidence underlying the model.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.